NCLEX ABRAMS' CLINICAL DRUG
THERAPY QUESTIONS WITH
CORRECT ANSWERS 2025/2026
1.1ATheAnurseAisAcaringAforAaAwomanAwhoAhasAstrongAbeliefsAaboutAnotAputtingAanythingAunna
turalAintoAherAbody.AItAisAmostAaccurateAtoAsayAthatAmostAmodernAmedicationsAare
A.AnaturalAproductsAderivedAfromAplants
B.AnaturalAproductsAderivedAfromAminerals
C.AsyntheticAproductsAmanufacturedAinAlaboratories
D.AsyntheticAmodificationsAofAnaturalAproductsA-AcorrectAanswersC.A
Rationale:AAlthoughAmostAolderAdrugsAoriginatedAasAplants,Aminerals,AorAotherAnaturalAproduc
ts,AnewerAdrugsAareAmainlyAsynthetic.ASyntheticAdrugsAareAstandardizedAandAthereforeAmoreAc
onsistentAinAtheirAcharacteristicsAandAeffectsAthanAnaturalAproducts.
1.2ATheAnurseAisAtakingAcareAofAaAmanAwhoAisAconfusedAaboutAtheAdifferentAmedicationsAheAisA
prescribed.AHeAnotesAthatAsomeAofAtheAdrugAnamesAhaveAchangedAoverAtheAcourseAofAtimeAheA
hasAbeenAtakingAthem.AWhenAcounselingAhim,AitAisAmostAimportantAtoAkeepAtheAfollowingAstat
ementAinAmind:
A.AAAdrugAcanAbelongAtoAonlyAoneAgroupAorAclassification.
B.AAAprototypeAdrugAisAtheAstandardAbyAwhichAsimilarAdrugsAareAcompared.
C.ADrugAgroupsAandAprototypesAchangeAfrequently,AandAknowledgeAaboutAaAprototypeAcannot
AguideAknowledgeAaboutAotherAdrugsAinAtheAsameAclass.
D.ATheAgenericAnameAofAaAdrugAchangesAamongAmanufacturers.A-AcorrectAanswersB.A
Rationale:ATheAfirstAdrugAtoAbeAdevelopedAinAaAgroupAisAusuallyAconsideredAtheAprototypeAorA
mainAexampleAofAtheAgroup,AandAsimilarAdrugsAthatAareAdevelopedAlaterAareAcomparedAtoAtheA
prototype.AKnowledgeAofAtheAprototypeAdrugAcanAhelpAtheAnurseAunderstandAtheAactionsAofAo
therAdrugsAinAtheAclass.AMostAdrugsAcanAbelongAtoAmultipleAgroupsA(e.g.,AaAtherapeuticAgroup,A
aAchemicalAgroup),AdependingAonAvariousAcharacteristics.ADrugAgroupsAandAprototypesAareAus
uallyAquiteAstable,AandAmostAnewAdrugsAfitAintoAaAknownAclassification.ATheAtradeAorAbrandAna
meAchangesAamongAmanufacturers,AbutAtheAgenericAnameAstaysAtheAsame.
1.3AInAunderstandingAtheAuseAofAcontrolledAsubstancesAforApatients,AitAisAimportantAthatAtheAn
urseAknowsAthatAcontrolledAdrugsAare
A.AcategorizedAaccordingAtoAprescriptionAorAnonprescriptionAstatus
B.AregulatedAbyAstateAandAlocalAlawsAmoreAthanAfederalAlaws
, C.AthoseAthatAmustAdemonstrateAhighAstandardsAofAsafety
D.AscheduledAaccordingAtoAmedicalAuseAandApotentialAforAabuseA-AcorrectAanswersD.A
Rationale:AControlledAorAscheduledAdrugsAareAcategorizedAbyAfederalAlawAaccordingAtoAuseAan
dAabuseApotential.ATheseAdrugsAhaveAregulationsAthatAgovernAprescribing,Adispensing,Aadminis
tering,AandArecord-
keeping.AAlmostAallAscheduledAdrugsArequireAprescriptionsA(i.e.,AcannotAlegallyAbeAsoldAoverAth
eAcounter).ABasicAlawsAareAfederal,AandAstatesAandAlocalAcommunitiesAmayAenactAadditionalAla
ws.
1.4AAApatientAisAaskingAwhatAtheAdifferenceAisAbetweenAaAprescriptionAforA800AmgAofAaAmedicat
ionAthatAcanAbeApurchasedAonAanAOTCAbasisAasAaA200-
mgAtablet.AToAaddressAthisAissue,AitAisAimportantAthatAtheAnurseAknowsAthatAOTCAdrugs
A.AareAconsideredAsafeAforAanyAconsumerAtoAuse
B.AareAnotAavailableAforAtreatmentAofAmostAcommonlyAoccurringAsymptoms
C.AoftenAdifferAinAindicationsAforAuseAandArecommendedAdosagesAfromAtheirAprescriptionAversi
ons
D.AareApaidAforAbyAmostAinsuranceApoliciesA-AcorrectAanswersC.A
Rationale:AUsesAmayAbeAdifferent,AandArecommendedAdosagesAofAover-the-
counterA(OTC)AdrugsAareAusuallyAlowerAthanAprescriptionAversions.ALabelsAofAOTCAdrugsAcontai
nAaAlistingAofApeopleAwhoAshouldAnotAuseAtheAdrugs,AandAtheAdrugsAareAnotAsafeAforAeveryone.A
ManyAOTCAdrugsAareAavailableAtoAtreatAcoldAsymptoms,Aheartburn,Aconstipation,AandAotherAco
mmonAproblems.AInsuranceAcompaniesAdoAnotApayAforAOTCAdrugs.
1.5AAAmanAisAveryAupsetAwithAaAdrugArecallAofAaAmedicationAheAhasAbeenAtakingAforAaAlongAtime
.AHeAstatesAthatAheAfeelsAlikeAheAcanAnoAlongerAtrustAanyoneAtoAprotectAhim.AInAresponseAtoAhis
AquestionsAaboutAtheAprocessAofAdrugAdevelopment,AitAisAimportantAtoAknowAthatAwithAaAnewA
drug,AtheAU.S.AFoodAandADrugAAdministrationA(FDA)AisAresponsibleAfor
A.AtestingAtheAdrugAwithAanimals
B.AtestingAtheAdrugAwithAhealthyApeople
C.AmarketingAtheAdrugAtoAhealthAcareAproviders
D.AevaluatingAtheAdrugAforAsafetyAandAeffectivenessA-AcorrectAanswersD.A
Rationale:ATheAU.S.AFoodAandADrugAAdministrationAreviewsAstudiesAreportedAbyAothers,Amainl
yApharmaceuticalAcompanies,AandAdeterminesAwhetherAaAdrugAisAsufficientlyAsafeAandAeffectiv
eAtoAbeAmarketed.ATheAdrugAmanufacturerAisAresponsibleAforAtestingAtheAdrugA(inAanimalsAandA
people)AandAmarketingAtheAdrug.
THERAPY QUESTIONS WITH
CORRECT ANSWERS 2025/2026
1.1ATheAnurseAisAcaringAforAaAwomanAwhoAhasAstrongAbeliefsAaboutAnotAputtingAanythingAunna
turalAintoAherAbody.AItAisAmostAaccurateAtoAsayAthatAmostAmodernAmedicationsAare
A.AnaturalAproductsAderivedAfromAplants
B.AnaturalAproductsAderivedAfromAminerals
C.AsyntheticAproductsAmanufacturedAinAlaboratories
D.AsyntheticAmodificationsAofAnaturalAproductsA-AcorrectAanswersC.A
Rationale:AAlthoughAmostAolderAdrugsAoriginatedAasAplants,Aminerals,AorAotherAnaturalAproduc
ts,AnewerAdrugsAareAmainlyAsynthetic.ASyntheticAdrugsAareAstandardizedAandAthereforeAmoreAc
onsistentAinAtheirAcharacteristicsAandAeffectsAthanAnaturalAproducts.
1.2ATheAnurseAisAtakingAcareAofAaAmanAwhoAisAconfusedAaboutAtheAdifferentAmedicationsAheAisA
prescribed.AHeAnotesAthatAsomeAofAtheAdrugAnamesAhaveAchangedAoverAtheAcourseAofAtimeAheA
hasAbeenAtakingAthem.AWhenAcounselingAhim,AitAisAmostAimportantAtoAkeepAtheAfollowingAstat
ementAinAmind:
A.AAAdrugAcanAbelongAtoAonlyAoneAgroupAorAclassification.
B.AAAprototypeAdrugAisAtheAstandardAbyAwhichAsimilarAdrugsAareAcompared.
C.ADrugAgroupsAandAprototypesAchangeAfrequently,AandAknowledgeAaboutAaAprototypeAcannot
AguideAknowledgeAaboutAotherAdrugsAinAtheAsameAclass.
D.ATheAgenericAnameAofAaAdrugAchangesAamongAmanufacturers.A-AcorrectAanswersB.A
Rationale:ATheAfirstAdrugAtoAbeAdevelopedAinAaAgroupAisAusuallyAconsideredAtheAprototypeAorA
mainAexampleAofAtheAgroup,AandAsimilarAdrugsAthatAareAdevelopedAlaterAareAcomparedAtoAtheA
prototype.AKnowledgeAofAtheAprototypeAdrugAcanAhelpAtheAnurseAunderstandAtheAactionsAofAo
therAdrugsAinAtheAclass.AMostAdrugsAcanAbelongAtoAmultipleAgroupsA(e.g.,AaAtherapeuticAgroup,A
aAchemicalAgroup),AdependingAonAvariousAcharacteristics.ADrugAgroupsAandAprototypesAareAus
uallyAquiteAstable,AandAmostAnewAdrugsAfitAintoAaAknownAclassification.ATheAtradeAorAbrandAna
meAchangesAamongAmanufacturers,AbutAtheAgenericAnameAstaysAtheAsame.
1.3AInAunderstandingAtheAuseAofAcontrolledAsubstancesAforApatients,AitAisAimportantAthatAtheAn
urseAknowsAthatAcontrolledAdrugsAare
A.AcategorizedAaccordingAtoAprescriptionAorAnonprescriptionAstatus
B.AregulatedAbyAstateAandAlocalAlawsAmoreAthanAfederalAlaws
, C.AthoseAthatAmustAdemonstrateAhighAstandardsAofAsafety
D.AscheduledAaccordingAtoAmedicalAuseAandApotentialAforAabuseA-AcorrectAanswersD.A
Rationale:AControlledAorAscheduledAdrugsAareAcategorizedAbyAfederalAlawAaccordingAtoAuseAan
dAabuseApotential.ATheseAdrugsAhaveAregulationsAthatAgovernAprescribing,Adispensing,Aadminis
tering,AandArecord-
keeping.AAlmostAallAscheduledAdrugsArequireAprescriptionsA(i.e.,AcannotAlegallyAbeAsoldAoverAth
eAcounter).ABasicAlawsAareAfederal,AandAstatesAandAlocalAcommunitiesAmayAenactAadditionalAla
ws.
1.4AAApatientAisAaskingAwhatAtheAdifferenceAisAbetweenAaAprescriptionAforA800AmgAofAaAmedicat
ionAthatAcanAbeApurchasedAonAanAOTCAbasisAasAaA200-
mgAtablet.AToAaddressAthisAissue,AitAisAimportantAthatAtheAnurseAknowsAthatAOTCAdrugs
A.AareAconsideredAsafeAforAanyAconsumerAtoAuse
B.AareAnotAavailableAforAtreatmentAofAmostAcommonlyAoccurringAsymptoms
C.AoftenAdifferAinAindicationsAforAuseAandArecommendedAdosagesAfromAtheirAprescriptionAversi
ons
D.AareApaidAforAbyAmostAinsuranceApoliciesA-AcorrectAanswersC.A
Rationale:AUsesAmayAbeAdifferent,AandArecommendedAdosagesAofAover-the-
counterA(OTC)AdrugsAareAusuallyAlowerAthanAprescriptionAversions.ALabelsAofAOTCAdrugsAcontai
nAaAlistingAofApeopleAwhoAshouldAnotAuseAtheAdrugs,AandAtheAdrugsAareAnotAsafeAforAeveryone.A
ManyAOTCAdrugsAareAavailableAtoAtreatAcoldAsymptoms,Aheartburn,Aconstipation,AandAotherAco
mmonAproblems.AInsuranceAcompaniesAdoAnotApayAforAOTCAdrugs.
1.5AAAmanAisAveryAupsetAwithAaAdrugArecallAofAaAmedicationAheAhasAbeenAtakingAforAaAlongAtime
.AHeAstatesAthatAheAfeelsAlikeAheAcanAnoAlongerAtrustAanyoneAtoAprotectAhim.AInAresponseAtoAhis
AquestionsAaboutAtheAprocessAofAdrugAdevelopment,AitAisAimportantAtoAknowAthatAwithAaAnewA
drug,AtheAU.S.AFoodAandADrugAAdministrationA(FDA)AisAresponsibleAfor
A.AtestingAtheAdrugAwithAanimals
B.AtestingAtheAdrugAwithAhealthyApeople
C.AmarketingAtheAdrugAtoAhealthAcareAproviders
D.AevaluatingAtheAdrugAforAsafetyAandAeffectivenessA-AcorrectAanswersD.A
Rationale:ATheAU.S.AFoodAandADrugAAdministrationAreviewsAstudiesAreportedAbyAothers,Amainl
yApharmaceuticalAcompanies,AandAdeterminesAwhetherAaAdrugAisAsufficientlyAsafeAandAeffectiv
eAtoAbeAmarketed.ATheAdrugAmanufacturerAisAresponsibleAforAtestingAtheAdrugA(inAanimalsAandA
people)AandAmarketingAtheAdrug.
